Evidence map›Paper›PMID 35289688›Full record

Trial reportAIDS patient care and STDs2022

Acceptability of the Dapivirine Vaginal Ring in Postmenopausal US Women.

Mary Kate Shapley-Quinn, Nicole Laborde, Ellen Luecke, Craig Hoesley, Robert A Salata, Sherri Johnson, Annalene Nel, Lydia Soto-Torres, Beatrice A Chen, Ariane van der Straten

Open access · hybridAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph

Trial report in AIDS patient care and STDs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 2 countries.

Mary Kate Shapley-QuinnGlobal Public Health Impact Center, RTI International, Berkeley, California, USA.ORCID 0000-0001-9805-3132
Nicole LabordeIndependent Consultant, San Rafael, California, USA.ORCID 0000-0002-7273-2476
Ellen LueckeGlobal Public Health Impact Center, RTI International, Berkeley, California, USA.
Craig HoesleyDepartment of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Robert A SalataUniversity Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Sherri JohnsonFHI 360, Durham, North Carolina, USA.
Annalene NelInternational Partnership for Microbicides, Silver Spring, Maryland, USA.
Lydia Soto-TorresDivision of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.
Beatrice A ChenUniversity of Pittsburgh/Magee-Womens Research Institute, Pittsburgh, Pennsylvania, USA.
Ariane van der StratenDepartment of Medicine, Center for AIDS Prevention Studies, University of California, San Francisco, California, USA.
RTI International · USFamily Health International 360 · USInternational Partnership for Microbicides · USMagee-Womens Research Institute · USNational Institute of Allergy and Infectious Diseases · USRafael Advanced Defense Systems (Israel) · ILUniversity Hospitals of Cleveland · USUniversity of Alabama at Birmingham · USUniversity of California, San Francisco · US

Funding

Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
University of Pittsburgh Clinical Trials UnitUM1AI069494 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SUSAN L KOLETAR, John W Mellors · 2012 to 2026
$38.0M
NIAID NIH HHS UM1 AI069494NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

For women in the United States who remain sexually active beyond child-bearing years, susceptibility to HIV infection remains, yet condom use is low. We assessed acceptability of the dapivirine vaginal ring (ring) among 96 postmenopausal US women enrolled in a placebo-controlled multisite phase II trial of the ring, using questionnaires and in-depth interviews. Three quarters of women reported "perfect" adherence (ring never out) over the 3-month trial period. At study exit, the ring was found to be very easy to use by 72%, very comfortable to wear by 65%, and 4% reported it ever interfered with their daily activities. The most common worries among participants at preinitiation had decreased significantly at study exit (e.g., worries about inserting the ring declined from 46% to 6%, discomfort during daily activities from 53% to 3%, ring not staying in place from 48% to 14%, all

Indexed as

Anti-HIV AgentsContraceptive Devices, FemaleHIV InfectionsFemaleHumansMalePostmenopausePyrimidinesAnti-HIV AgentsDapivirinePyrimidinesacceptability and preferencedapivirineintravaginal ringmicrobicidespostmenopausalpre-exposure prophylaxis

Identifiers

PMID35289688
PMCPMC8971982
OpenAlexW4220738519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.